Evidence map›Paper›PMID 32758689›Full record

Trial reportInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2020

SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial.

Fang Zheng, Yanwen Zhou, Zhiguo Zhou, Fei Ye, Baoying Huang, Yaxiong Huang, Jing Ma, Qi Zuo, Xin Tan, Jun Xie and 14 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 6 pooled it
1.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 6 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. COVID-19 drug discovery and treatment options.Nature reviews. Microbiology · 2024
    Review
  9. Article
  10. Article
  11. Severe COVID-19: Drugs and Clinical Trials.Journal of clinical medicine · 2023
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. SARS-CoV-2 Antiviral Therapy.Clinical microbiology reviews · 2021
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 1 country.

Fang ZhengDepartment of Infectious Diseases, The First Hospital of Changsha, Changsha, China.
Yanwen ZhouDepartment of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.
Zhiguo ZhouDepartment of Respiratory Medicine, The First Hospital of Changsha, Changsha, China.
Fei YeNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Baoying HuangNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yaxiong HuangDepartment of Infectious Diseases, The First Hospital of Changsha, Changsha, China.
Jing MaDepartment of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.
Qi ZuoDepartment of Intensive Care Unit, The First Hospital of Changsha, Changsha, China.
Xin TanDepartment of Pediatrics, The First Hospital of Changsha, Changsha, China.
Jun XieDepartment of Internal Medicine, The First Hospital of Changsha, Changsha, China.
Peihua NiuNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Wenlong WangDepartment of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.
Yun XuDepartment of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.
Feng PengDepartment of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.
Ning ZhouDepartment of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.
Chunlin CaiDepartment of Infectious Diseases, The First Hospital of Changsha, Changsha, China.
Wei TangDepartment of Infectious Diseases, The First Hospital of Changsha, Changsha, China.
Xinqiang XiaoDepartment of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.
Yi LiDepartment of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.
Zhiguang ZhouKey Laboratory of Diabetes Immunology (Central South University), Ministry of Education, National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital, Central South University, Changsha, China.
Yongfang JiangDepartment of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: jiangyongfang@csu.edu.cn.
Yuanlin XieDepartment of Infectious Diseases, The First Hospital of Changsha, Changsha, China. Electronic address: 1286779459@qq.com.
Wenjie TanNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. Electronic address: tanwj@ivdc.chinacdc.cn.
Guozhong GongDepartment of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: gongguozhong@csu.edu.cn.
The First Hospital of Changsha · CNCentral South University · CNSecond Xiangya Hospital of Central South University · CNNational Institute for Viral Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe antiviral effects of Novaferon, a potent antiviral protein drug, on COVID-19 was evaluated in the laboratory, and in a randomized, open-label, parallel-group trial.

methodsIn the laboratory, Novaferon's inhibition of viral replication in cells infected with SARS-CoV-2, and prevention of SARS-CoV-2 entry into healthy cells was determined. Antiviral effects of Novaferon in COVID-19 patients with treatment of Novaferon, Novaferon plus Lopinavir/Ritonavir, or Lopinavir/Ritonavir were evaluated. The primary endpoint was the SARS-CoV-2 clearance rates on day six of treatment, and the secondary endpoint was the time to SARS-CoV-2 clearance.

resultsNovaferon inhibited viral replication (EC

conclusionsNovaferon exhibited anti-SARS-CoV-2 effects in vitro and in COVID-19 patients. These data justify further evaluation of Novaferon. TRIAL REGISTRATION NUMBER: Number ChiCTR2000029496 at the Chinese Clinical Trial Registry (http://www.chictr.org.cn/).

Indexed as

Administration, InhalationAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentFemaleHumansInterferonsMalePandemicsPneumonia, ViralRecombinant ProteinsSARS-CoV-2Virus ReplicationAntiviral AgentsInterferonsrecombinant interferon alpha 2b-like proteinRecombinant ProteinsAerosolized inhalationAntiviral drugCOVID-19Lopinavir/RitonavirNovaferonSARS-CoV-2Viral clearance

Identifiers

PMID32758689
PMCPMC7397938
OpenAlexW3046480983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.